Prodrug Strategy for PROTACs: High Efficiency and Low Toxicity.

Area of Science:

• Biochemistry
• Pharmacology
• Drug Discovery

Background:

• Proteolysis-targeting chimeras (PROTACs) utilize endogenous E3 ligases for targeted protein degradation.
• PROTACs offer a promising approach for
• PROTACs have shown potential in treating diseases like cancer, expanding drug development avenues.

Purpose of the Study:

• To review activation methods and optimization strategies for PROTACs.
• To discuss PROTAC prodrugs as a strategy to overcome limitations in clinical implementation.
• To explore PROTAC delivery systems for improved druggability.

Main Methods:

• Review of current literature on PROTAC technology.
• Analysis of PROTAC prodrug activation mechanisms (light, enzymes, immune components).
• Examination of various PROTAC delivery systems (polymers, conjugates, liposomes, albumin).

Main Results:

• PROTACs offer a novel mechanism for targeted protein degradation, addressing previously undruggable targets.
• PROTAC prodrugs enable spatiotemporally controlled protein degradation, mitigating systemic toxicity and improving bioavailability.
• Diverse delivery systems are being developed to enhance PROTAC druggability and therapeutic potential.

Conclusions:

• PROTAC prodrugs represent a significant advancement in targeted protein degradation therapy.
• Optimized activation and delivery strategies are crucial for the successful clinical translation of PROTACs.
• Further research into PROTAC prodrugs and delivery systems will expand their therapeutic applications.